Similar Natural Products in NPASS
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC476128 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 16758 |
0.1-0.2 | 10588 |
0.2-0.3 | 2030 |
0.3-0.4 | 1166 |
0.4-0.5 | 286 |
0.5-0.6 | 53 |
0.6-0.7 | 4 |
0.7-0.8 | 2 |
0.8-0.85 | 1 |
0.85-0.9 | 0 |
0.9-0.95 | 1 |
0.95-1 | 0 |
  Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC476128 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 889 |
0.1-0.2 | 3370 |
0.2-0.3 | 2499 |
0.3-0.4 | 1547 |
0.4-0.5 | 746 |
0.5-0.6 | 90 |
0.6-0.7 | 16 |
0.7-0.8 | 2 |
0.8-0.85 | 0 |
0.85-0.9 | 2 |
0.9-0.95 | 0 |
0.95-1 | 0 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8557 |
High Similarity |
NPD9194 |
Approved |
0.8557 |
High Similarity |
NPD9193 |
Approved |
0.7732 |
Intermediate Similarity |
NPD8565 |
Clinical (unspecified phase) |
0.757 |
Intermediate Similarity |
NPD8571 |
Phase 3 |
0.6949 |
Remote Similarity |
NPD420 |
Discontinued |
0.6833 |
Remote Similarity |
NPD1734 |
Clinical (unspecified phase) |
0.6789 |
Remote Similarity |
NPD8566 |
Approved |
0.6748 |
Remote Similarity |
NPD2191 |
Discontinued |
0.6637 |
Remote Similarity |
NPD9071 |
Phase 3 |
0.6484 |
Remote Similarity |
NPD3678 |
Phase 2 |
0.6378 |
Remote Similarity |
NPD1705 |
Discontinued |
0.6341 |
Remote Similarity |
NPD306 |
Approved |
0.6308 |
Remote Similarity |
NPD4763 |
Clinical (unspecified phase) |
0.622 |
Remote Similarity |
NPD8832 |
Approved |
0.6212 |
Remote Similarity |
NPD2602 |
Clinical (unspecified phase) |
0.6139 |
Remote Similarity |
NPD8584 |
Approved |
0.6107 |
Remote Similarity |
NPD1264 |
Phase 2 |
0.6074 |
Remote Similarity |
NPD4765 |
Approved |
0.6074 |
Remote Similarity |
NPD4764 |
Approved |
0.6016 |
Remote Similarity |
NPD9366 |
Approved |
0.5985 |
Remote Similarity |
NPD2618 |
Phase 1 |
0.5909 |
Remote Similarity |
NPD9210 |
Phase 2 |
0.5833 |
Remote Similarity |
NPD162 |
Approved |
0.5833 |
Remote Similarity |
NPD427 |
Approved |
0.5833 |
Remote Similarity |
NPD426 |
Approved |
0.5833 |
Remote Similarity |
NPD428 |
Approved |
0.5822 |
Remote Similarity |
NPD491 |
Approved |
0.58 |
Remote Similarity |
NPD4143 |
Clinical (unspecified phase) |
0.5775 |
Remote Similarity |
NPD1988 |
Phase 1 |
0.5734 |
Remote Similarity |
NPD4709 |
Approved |
0.5726 |
Remote Similarity |
NPD8861 |
Approved |
0.5726 |
Remote Similarity |
NPD8862 |
Approved |
0.5726 |
Remote Similarity |
NPD8859 |
Approved |
0.5714 |
Remote Similarity |
NPD174 |
Discontinued |
0.5693 |
Remote Similarity |
NPD799 |
Phase 1 |
0.568 |
Remote Similarity |
NPD8831 |
Approved |
0.568 |
Remote Similarity |
NPD8833 |
Approved |
0.5678 |
Remote Similarity |
NPD8836 |
Approved |
0.5649
|
Remote Similarity |
NPD8826 |
Approved |